A phase I clinical and pharmacokinetic study of the dolastatin analogue cemadotin administered as a 5-day continuous intravenous infusion
Jeffrey G. Supko, Thomas J. Lynch, Jeffrey W. Clark, Robert Fram, Lee F. Allen, Raja Velagapudi, Donald W. Kufe, Joseph Paul Eder JrVolume:
46
Language:
english
Pages:
10
DOI:
10.1007/s002800000152
Date:
October, 2000
File:
PDF, 154 KB
english, 2000